

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

EP 1,100,454

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/48, 33/40, A01N 31/02, C11D 3/48	A1	(11) International Publication Number: WO 00/06116 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/17339 (22) International Filing Date: 30 July 1999 (30.07.99) (30) Priority Data: 60/094,775 31 July 1998 (31.07.98) US 09/330,127 11 June 1999 (11.06.99) US (71)(72) Applicant and Inventor: MURAD, Howard [US/US]; 4265 Marina City Drive, Penthouse 11, Marina del Rey, CA 90292 (US). (74) Agents: FANUCCI, Allan, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MANAGING SKIN CONDITIONS (57) Abstract This application relates to a stable pharmaceutical composition and methods for the cleansing of skin to facilitate the prevention, treatment, and management of skin conditions, such as seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, and the like, including a sufficient amount of an acidic component of a hydroxyacid or tannic acid, or a pharmaceutically acceptable salt thereof, to exfoliate a portion of the skin, a sufficient amount of stabilized hydrogen peroxide to facilitate cleansing of the skin without substantial irritation thereof, and an antimicrobial agent in an amount sufficient to inhibit or reduce microorganisms on the skin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**PHARMACEUTICAL COMPOSITIONS AND METHODS FOR
MANAGING SKIN CONDITIONS**

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of provisional Application No.
5 60/094,775, filed July 31, 1998.

TECHNICAL FIELD

This application relates to pharmaceutical compositions and methods to
cleanse skin and facilitate the prevention, treatment, and management of skin conditions.

10

BACKGROUND OF THE INVENTION

Human skin is a composite material of the epidermis and the dermis. The
topmost part of the epidermis is the stratum corneum. This layer is the stiffest layer of the
skin, as well as the one most affected by the surrounding environment. Below the stratum
15 corneum is the internal portion of the epidermis. Below the epidermis, the topmost layer of
the dermis is the papillary dermis, which is made of relatively loose connective tissues that
define the micro-relief of the skin. The reticular dermis, disposed beneath the papillary
dermis, is tight, connective tissue that is spatially organized. The reticular dermis is also
associated with coarse wrinkles. At the bottom of the dermis lies the subcutaneous layer.

20 The principal functions of the skin include protection, excretion, secretion,
absorption, thermoregulation, pigmentogenesis, accumulation, sensory perception, and
regulation of immunological processes. These functions are detrimentally affected by, for
example, dryness, yeast, and structural changes in the skin, such as due to aging and
excessive sun exposure.

25 Various pharmaceuticals have been used for the treatment or prevention of
skin conditions, including skin cleansing compositions. Some of these compositions are
discussed below.

Canadian Patent No. 1,174,976 discloses a germ-killing skin medication
including two gels to be applied and mixed *in situ*, the first gel having sodium chlorite in an
30 aqueous form and the second gel having lactic acid in an aqueous gel.

Great Britain Application No. 2,076,286 A discloses a dermatological
composition of an oil medium dispersed in an aqueous medium that contains hydrogen

peroxide, a buffer to maintain the composition below a pH of 7, and a starch gelled *in situ*. The buffer may include lactic, citric, tartaric, maleic, or hydroxysuccinic acids with an acid salt.

Great Britain Application No. 2,189,394 A discloses a concentrate that can
5 be mixed with hydrogen peroxide to become an effective disinfectant for water, foodstuff, animal feeds, equipment, packages, and the like. The concentrate includes an inorganic acid with a pH less than 1.6, a silver compound or colloidal silver, an organic acid stabilizer such as tartaric, lactic, salicylic, or citric acid, and optionally gelatin.

European Patent Application No. 0,191,214 A2 discloses a cosmetic liquid
10 cleanser for treating blemished, scarred, or inflamed skin having boric acid or borax, ammonium hydroxide, a peroxide, and optionally salicylic acid.

European Patent No. 0,250,539 B1 discloses a stabilized aqueous hydrogen peroxide composition having 0.1 to 4 weight percent hydrogen peroxide and 0.5 to 5 weight percent β -crystals of one or more lipids selected from monoglycerides of fatty acids,
15 ascorbic acid, phosphate or lactic acid esters of fatty acids and monoglycerol ethers, said fatty acids and ether chains being saturated and having 12 to 18 carbons.

European Patent No. 0,425,507 B1 discloses compositions for treating abnormal or damaged conditions of the epithelium including skin, which include 0.01 to 12 weight percent of an activated protein containing at least 0.5 weight percent cysteine, 0.1 to
20 15 weight percent of a reducing agent to reduce cystine to cysteine, and 81.0 to 99.889 weight percent water, acids, bases, buffering agents, emulsifying agents, thickeners, solvents, preservatives, coloring agents, and perfuming agents. The reducing agent may be a salt of a thioglycolic acid. In a preferred embodiment, the composition also includes an oxidizing agent, such as hydrogen peroxide.

25 U.S. Patent No. 3,297,456 discloses cleaning and polishing compositions, particularly for floor waxing, having lactic acid, methanol, hydrogen peroxide, and aqua ammonia in a particular ratio.

U.S. Patent Nos. 4,015,058 and 4,015,059 disclose stable peroxy-containing concentrates useful for the production of microbicidal agents consisting essentially of an
30 aqueous mixture of 0.5 to 20 weight percent peracetic or perpropionic acid or their precursors, 25 to 40 weight percent hydrogen peroxide, and optionally up to 5 weight percent anionic surface-active compounds of the sulfonate and sulfate type. Also disclosed

are compositions that further include 0.25 to 10 weight percent organic phosphonic acid capable of sequestering bivalent metal cations and their water-soluble acid salts.

U.S. Patent No. 4,203,765 discloses an aqueous acidic etch-bleach solution of hydrogen peroxide, iron ions, and inorganic anions that form a silver salt, such that in the dissolved state the solution contains citric acid and a polymer of alkylene oxide units for
5 stabilization of the hydrogen peroxide.

U.S. Patent No. 4,438,102 discloses compositions containing gelatin, hydrogen peroxide, ammonium hydroxide, thioglycolic acid, and a lower alkanol to promote the growth of dermal and epidermal tissue.

10 U.S. Patent No. 4,534,945 discloses an aqueous 25 to 35 weight percent solution of hydrogen peroxide stabilized against decomposition with up to 1.4 mg/L tin, which is maintained in solution by particular amounts of phosphate in the form of phosphonic acid and hydroxycarboxylic acid.

U.S. Patent No. 4,557,935 discloses a germicidal composition of hydrophilic
15 lipid crystals of 1-monolaurin, and preferably 1-monomyristin, and hydrogen peroxide, whereby the former stabilize the latter. Optionally, the compositions further contain salicylic acid.

U.S. Patent No. 4,900,721 discloses liquid, aqueous disinfectants based on alcohol and hydrogen peroxide that contain one or more C_{2-8} alcohols, hydrogen peroxide or
20 a hydrogen peroxide forming compound, one or more carboxylic acids, one or more microbicidally active nitrogen-containing organic compounds, one or more microbicidally active phenolic compounds for disinfection of the skin and mucous membrane.

U.S. Patent No. 5,139,788 discloses an antimicrobial surface sanitizing composition having a diluent and antimicrobial agent of an antimicrobially effective amount
25 of alpha-hydroxyacid substituted mono- or di-carboxylic acid and an antimicrobially effective amount of hydrogen peroxide, such that the composition leaves a non-contaminating residue after contact with surfaces to be disinfected.

U.S. Patent No. 5,693,318 discloses phosphate esters for the improvement of water solubility of salicylic acid and peroxide compounds in an aqueous cleanser.

30 Despite these references, a stable composition of hydrogen peroxide, a hydroxy acid, and an antimicrobial agent has not been prepared and used for cleansing skin and managing skin conditions. Thus, there is still a need for improved pharmaceutical

compositions and methods capable of cleansing the skin to facilitate the prevention, treatment, and management of skin conditions, such as folliculitis, seborrheic dermatitis, psoriasis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, and the like. The present invention advantageously provides pharmaceutical
5 compositions and methods for cleansing skin to facilitate the prevention, treatment, and management of one or more skin conditions.

SUMMARY OF THE INVENTION

The present invention relates to a skin cleansing pharmaceutical
10 composition, preferably for administration to a patient, including an acidic component having a hydroxy acid or tannic acid, or a pharmaceutically acceptable salt thereof, in an amount sufficient to exfoliate at least a portion of the skin, hydrogen peroxide in an amount sufficient to cleanse the skin without substantial irritation thereof, and an antimicrobial agent in an amount sufficient to at least inhibit microorganisms on the skin. In a preferred
15 embodiment, the composition further includes a pharmaceutically acceptable carrier or excipient.

In one embodiment, the acidic component includes an alpha-hydroxy acid, beta-hydroxy acid, or tannic acid, and the antimicrobial agent includes a bacteriocide. In a preferred embodiment, the acidic component includes glycolic acid, lactic acid, citric acid,
20 salicylic acid, or tannic acid. In another preferred embodiment, the bacteriocide includes triclosan.

Advantageously, the acidic component is present in an amount from about 0.1 to 8 weight percent, the hydrogen peroxide is present in an amount from about 0.01 to 6 weight percent, and the antimicrobial agent is present in an amount from about 0.1 to 1.5
25 weight percent of the composition. In a preferred embodiment, the composition further includes at least one of a surfactant, a stabilizer, a preservative, a moisturizer, anti-inflammatory agent, anti-oxidant, and a coloring agent, which together may be present in an amount from about 10.1 to 99.1 weight percent of the composition.

The acidic component can include an amount of citric acid sufficient to
30 inhibit hydrogen peroxide decomposition over at least three months. In a more preferred embodiment, the amount of citric acid is sufficient to inhibit hydrogen peroxide

decomposition at 40°C over at least three months. The invention also relates to a gel, paste, cream, lotion, emulsion, or ointment that includes these pharmaceutical compositions.

The invention further relates to a method of managing a skin condition by administering to a patient a therapeutically effective amount of: (1) an acidic component
5 including a hydroxy acid or tannic acid, or a pharmaceutically acceptable salt thereof, (2) hydrogen peroxide, and (3) an antimicrobial agent to at least inhibit the growth of microorganisms on the skin that contributes to, or causes, the skin condition.

The types of skin conditions that can be treated include seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, or impetigo or other inflammatory
10 skin conditions. The administration of the components may be topical, such as by at least one of a gel, paste, cream, lotion, emulsion, or ointment. About 1 mg to 10,000 mg of the acidic component, hydrogen peroxide, and antimicrobial agent are administered together for satisfactory results in most cases. In a preferred embodiment, the acidic component, hydrogen peroxide, and antimicrobial agent are administered concurrently. In another
15 embodiment, the acidic component, hydrogen peroxide, and antimicrobial agent are administered concurrently with at least one additional pharmaceutical composition for the prevention or treatment of a skin condition. In this embodiment, the method further includes administering at least one of a surfactant, stabilizer, preservative, moisturizer, anti-inflammatory agent, anti-oxidant, or coloring agent. Alternatively, the acidic component
20 can include an alpha-hydroxy acid, beta-hydroxy acid, or tannic acid and the antimicrobial agent can include a bactericide. In a more preferred embodiment, the acidic component includes glycolic, lactic, tannic, citric, or salicylic acid, and the bactericide includes triclosan.

25 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A formulation for the prevention, treatment, and management of skin conditions, such as seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, and the like, has now been discovered. Moreover, the management of these skin conditions may advantageously be
30 accomplished by the administration of the pharmaceutical composition of the present invention.

The term "skin conditions," as used herein, means conditions present anywhere on the skin including seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, and the like.

The terms "managing" or "management," as used herein, includes one or
5 more of the prevention, treatment, or modification of a skin condition.

The term "inhibit hydrogen peroxide decomposition," as used herein, means to at least stop the rate of decomposition from increasing, preferably to inhibit the decomposition entirely, and more preferably to substantially inhibit the decomposition altogether. "Substantially inhibit," as used herein, means that less than about 10 weight
10 percent, preferably less than about 3 weight percent, and more preferably less than about 1 weight percent, of the hydrogen peroxide decomposes over a three month period of time.

Methods for administering the compositions herein are also encompassed by the invention. Such methods are used for the prevention, treatment, or management of one or more of: eczema, psoriasis, folliculitis, scaling, seborrhea or seborrheic dermatitis,
15 rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, all while substantially avoiding irritation to the skin. The compositions may be prepared in high concentrations for administration as a cleanser to be removed shortly thereafter, as well as in lower concentrations that are safer for products that can remain in contact with the skin for longer times.

20 The pharmaceutical compositions of the invention include the combination of a number of different components that interact to provide the desired management of the skin. The compositions include an acidic component including one or more mono- or poly-hydroxy acids or tannic acid, a mixture thereof, or a pharmaceutically acceptable salt or ester thereof. One of ordinary skill in the art will be readily able to select and prepare
25 suitable mono- or poly-hydroxy acids for use in the composition of the invention, for example, alkyl hydroxycarboxylic acids, aralkyl and aryl hydroxycarboxylic acids, polyhydroxy-carboxylic acids, and hydroxy-polycarboxylic acids. One of ordinary skill in the art would typically select one or more of the following mono- or poly-hydroxy acids: 2-hydroxyacetic acid (glycolic acid); 2-hydroxypropanoic acid (lactic acid); 2-methyl 2-
30 hydroxypropanoic acid; 2-hydroxybutanoic acid; phenyl 2-hydroxyacetic acid; phenyl 2-methyl 2-hydroxyacetic acid; 3-phenyl 2-hydroxyacetic acid; 2,3-dihydroxypropanoic acid; 2,3,4-trihydroxybutanoic acid; 2,3,4,5,6-pentahydroxyhexanoic acid; 2-hydroxydodecanoic

acid; 2,3,4,5-tetrahydroxypentanoic acid; 2,3,4,5,6,7-hexahydroxyheptanoic acid; diphenyl 2-hydroxyacetic acid; 4-hydroxymandelic acid; 4-chloromandelic acid; 3-hydroxybutanoic acid; 4-hydroxybutanoic acid; 2-hydroxyhexanoic acid; 5-hydroxydodecanoic acid; 12-hydroxydodecanoic acid; 10-hydroxydecanoic acid; 16-hydroxyhexadecanoic acid;

5 2-hydroxy-3-methylbutanoic acid; 2-hydroxy-4-methylpentanoic acid; 3-hydroxy-4-methoxymandelic acid; 4-hydroxy-3-methoxymandelic acid; 2-hydroxy-2-methylbutanoic acid; 3-(2-hydroxyphenyl) lactic acid; 3-(4-hydroxyphenyl) lactic acid; hexahydromandelic acid; 3-hydroxy-3-methylpentanoic acid; 4-hydroxydecanoic acid; 5-hydroxydecanoic acid; aleuritic acid; 2-hydroxypropanedioic acid;

10 2-hydroxybutanedioic acid; erythraric acid; threonic acid; arabaric acid; ribaric acid; xylaric acid; lyxaric acid; glucaric acid; galactaric acid; mannaric acid; gularic acid; allaric acid; altraric acid; idaric acid; talaric acid; 2-hydroxy-2-methylbutanedioic acid; citric acid, isocitric acid, agaricic acid, quinic acid, glucuronic acid, glucuronolactone, galacturonic acid, galacturonolactone, uronic acids, uronolactones, ascorbic acid, dihydroascorbic acid,

15 dihydroxytartaric acid, tropic acid, ribonolactone, gluconolactone, galactonolactone, gulonolactone, mannonolactone, citramalic acid; pyruvic acid, hydroxypyruvic acid, hydroxypyruvic acid phosphate and esters thereof; methyl pyruvate, ethyl pyruvate, propyl pyruvate, isopropyl pyruvate; phenyl pyruvic acid and esters thereof; methyl phenyl pyruvate, ethyl phenyl pyruvate, propyl phenyl pyruvate; formyl formic acid and esters thereof; methyl formyl formate, ethyl formyl formate, propyl formyl formate; benzoyl formic acid and esters thereof; methyl benzoyl formate, ethyl benzoyl formate and propyl benzoyl formate; 4-hydroxybenzoyl formic acid and esters thereof; 4-hydroxyphenyl pyruvic acid and esters thereof; and 2-hydroxyphenyl pyruvic acid and esters thereof. The hydroxy acids are preferably selected from one or more alpha-hydroxy acids or beta-

25 hydroxy acids, more preferably from glycolic, lactic, citric, tannic, or salicylic acid, and most preferably from citric and salicylic acids. It should be understood that one or more derivatives of the above acidic component, such as esters or lactones thereof, are also suitably used. One of ordinary skill in the art will also understand that various hydroxy acids described in U.S. Patent Nos. 5,547,988 and 5,422,370 are also suitable for use in the

30 compositions and methods of the invention. The acidic component is present in the composition and methods in an amount sufficient to exfoliate, *i.e.*, remove dead or dying skin cells, from at least a portion of the skin. The acidic component is typically present in

an amount from about 0.1 to 12 weight percent, preferably about 1 to 11 weight percent, more preferably from about 4 to 10 weight percent of the composition. For example, the acidic component may be from about 0.1 to 3 weight percent citric acid in combination with up to about 2 weight percent salicylic acid.

5 Compositions and methods for managing eczema, psoriasis, folliculitis, scaling, seborrhea or seborrheic dermatitis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, and the like, also include hydrogen peroxide and an antimicrobial agent. The hydrogen peroxide is present in an amount sufficient to cleanse at least a portion of the skin. "Cleanse" as used herein includes the removal of dirt, debris, air
10 pollutants, desquamating cells, and cutaneous secretions of the skin. The hydrogen peroxide is typically present in an amount from about 0.01 to 6 weight percent, preferably 0.05 to 4 weight percent, and more preferably 0.1 to 1 weight percent of the composition.

Any pharmaceutically acceptable antimicrobial agent may be used, preferably an antibacterial agent or antifungal agent, more preferably triclosan,
15 clotrimazole, farnesol, and the like, and mixtures thereof. Most preferably, triclosan is used as the antimicrobial agent. The antimicrobial agent is typically present in an amount from about 0.01 to 1.5 weight percent, preferably from about 0.1 to 1.2 weight percent, and more preferably from about 0.3 to 1 weight percent of the composition. The antimicrobial agent inhibits the formation, and may further reduce, the presence of microbes that cause redness,
20 inflammation, and irritation of the skin. Together, the acidic component, hydrogen peroxide, and antimicrobial agent facilitate exfoliation of dead skin, cleanse the skin, remove substances foreign to the skin, inhibit or reduce the presence of microorganisms, and generally facilitate management of skin conditions, such as seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory
25 skin conditions, and the like.

In a preferred embodiment, the compositions further include one or more of *Arnica Montana* (a healing herb); any vitamin A source including retinyl palmitate or other retinyl esters, retinoic acid, or Retinol; and Vitamin K. These components facilitate the skin cleansing and management of skin conditions accomplished by the acidic component,
30 hydrogen peroxide, and antimicrobial agent. The *Arnica Montana* facilitates skin healing and acts as an antiseptic and local anti-inflammatory, and, when used, is typically present in an amount from about 0.1 to 2 weight percent, preferably about 0.2 to 1 weight percent.

The Retinol facilitates normal skin production, particularly epidermal normalization, and, when used, is typically present in an amount from about 0.01 to 6 weight percent, preferably about 0.1 to 5 weight percent. The Vitamin K inhibits or suppresses inflammation and bruising (*i.e.*, acts as an anti-inflammatory and anti-bruising agent) and, when used, is
5 typically present in an amount from about 0.01 to 1 weight percent, preferably from about 0.1 to 0.5 weight percent.

In a preferred embodiment, the compositions all contain one or more surfactants, stabilizers, preservatives, moisturizers, coloring agents, anti-inflammatory agents, anti-oxidants, water, acids, bases, buffering agents, emulsifying agents, thickeners,
10 solvents, perfuming agents, and the like, and mixtures thereof. The water used is preferably deionized water. It should be understood that water includes the remainder of a given composition after other ingredients are determined. Although any pharmaceutically acceptable surfactant, stabilizer, preservative, moisturizer, coloring agent, acids, bases, buffering agents, emulsifying agents, thickeners, solvents, or perfuming agents may be
15 used, certain compounds or mixtures are preferred as discussed below.

Preferred surfactants, including both the foaming and non-foaming type, include sodium laureth sulfate, sodium laureth-13 carboxylate, disodium laureth sulfosuccinate, disodium cocoamphodiacetate, and the like, and mixtures thereof. More preferably, at least one amphoteric surfactant is included in the composition, such as
20 disodium cocoamphodiacetate. The amphoteric surfactant, in combination with citric acid, inhibits hydrogen peroxide decomposition. The surfactant component may be present in an amount from about 10 to 90 weight percent, preferably about 20 to 80, and more preferably about 30 to 70 weight percent of the composition.

A preferred stabilizer includes glycol stearate or PEG-150 distearate. The
25 stabilizer, when used, is typically present in an amount from about 0.1 to 5 weight percent of the composition.

Preferred preservatives include tetrasodium ethylene-diamine tetraacetic acid (EDTA), methylparaben, benzophenone-4, methylchloroisothiazolinone, methylisothiazolinone, and the like, and mixtures thereof. Preservatives, when used, are
30 typically present in an amount from about 0.01 to 6 weight percent, preferably about 0.05 to 4 weight percent, and more preferably from about 0.1 to 2 weight percent.

Preferred moisturizers include wheat protein (*e.g.*, laurdimonium hydroxypropyl hydrolyzed wheat protein), hair keratin amino acids, sodium peroxylinecarboic acid, panthenol, tocopherol (Vitamin E), dimethicone, and the like, and mixtures thereof. Sodium chloride may also be present, particularly when hair keratin amino acids are included as a moisturizer. Moisturizers, when used, are typically present in an amount from about 0.01 to 2 weight percent, preferably about 0.05 to 1.5 weight percent, more preferably from about 0.1 to 1 weight percent of the composition.

Preferred coloring agents include FD&C Green No. 3, Ext. D&C Violet No. 2, FD&C Yellow No. 5, FD&C Red No. 40, and the like, and mixtures thereof. The coloring agents, when used, are typically present in an amount from about 0.001 to 0.1 weight percent, and preferably from about 0.005 to 0.05 weight percent of the composition.

Preferred anti-inflammatory agents include any pharmaceutically acceptable compounds suitable for administration orally or topically, preferably at least one of aloe vera gel, aloe vera, licorice extract, pilewort, Canadian willow root, zinc, or allantoin, more preferably allantoin. The anti-inflammatory agents, when present, are used in an amount sufficient to inhibit or reduce inflammation, preferably in an amount from about 0.1 to 2 weight percent, preferably from about 0.3 to 1.5 weight percent, and more preferably from about 0.3 to 1 weight percent of the composition. It should be understood, with reference to managing skin conditions, that the anti-inflammatory agents facilitate inhibition or suppression of inflammation anywhere on the skin.

Anti-oxidants of both the enzymatic and non-enzymatic type may be included in the compositions and methods of the invention. For example, superoxide dismutase (SOD), catalase, and glutathione peroxidase are natural enzymatic anti-oxidants used by the body that may be supplemented with the compositions herein. Suitable non-enzymatic anti-oxidants include such as Vitamin E (*e.g.*, tocopherol), Vitamin C (ascorbic acid), carotenoids, Echinacoside and caffeoyl derivatives, oligomeric proanthocyanidins or proanthanols (*e.g.*, grape seed extract), silymarin (*e.g.*, milk thistle extract, *Silybum marianum*), ginkgo biloba, green tea polyphenols, and the like, and mixtures thereof. Carotenoids are powerful anti-oxidants, and they include beta-carotene, canthaxanthin, zeaxanthin, lycopene, lutein, crocetin, capsanthin, and the like. Indeed, any pharmaceutically acceptable compounds suitable for administration orally or topically may be used as an anti-oxidant in the compositions. Preferably, the anti-oxidant component includes Vitamin E,

Vitamin C, or a carotenoid. The anti-oxidant component, when used, is present in an amount sufficient to inhibit or reduce the effects of free-radicals at the scalp. The anti-oxidant component may be present in an amount from about 0.001 to 1 weight percent, preferably from about 0.01 to 0.5 weight percent of the composition.

5 The ranges of the components of the pharmaceutical composition may vary, but the active ingredients should be understood to add to 100 weight percent of the active pharmaceutical composition.

 The term "therapeutically effective amount" means that amount of the pharmaceutical composition that provides a therapeutic benefit in the treatment, prevention,
10 or management of one or more skin conditions.

 The magnitude of a prophylactic or therapeutic dose of the composition in the acute or chronic management of skin conditions will vary with the severity of the condition to be treated and the route of administration. The dose, and perhaps the dose frequency, will also vary according to the age, body weight, and response of the individual
15 patient. In general, a preferred topical daily dose range, in single or divided doses, for the conditions described herein should be from about 1 mg to 20,000 mg, more preferably about 2,000 mg to 16,000 mg, and most preferably about 6,000 mg to 10,000 mg of the active components (*i.e.*, excluding excipients and carriers).

 Those of ordinary skill in the art will also understand that topical
20 effectiveness of pharmaceuticals requires percutaneous absorption and bioavailability to the target site. Thus, the compositions and methods of the invention require penetration through the stratum corneum into the epidermal layers, as well as sufficient distribution to the sites targeted for pharmacologic action.

 It is further recommended that children, patients aged over 65 years, and
25 those with impaired renal or hepatic function initially receive low doses, and that they then be titrated based on individual response(s) or blood level(s). It may be necessary to use dosages outside these ranges in some cases, as will be apparent to those of ordinary skill in the art. Further, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response.

30 The term "unit dose" is meant to describe a single dose, although a unit dose may be divided, if desired. About 1 to 2 unit doses of the present invention are typically administered per day, preferably about 1 dose per day.

Any suitable route of administration may be employed for providing the patient with an effective dosage of the composition according to the methods of the present invention, including oral, intraoral, rectal, parenteral, topical, epicutaneous, transdermal, subcutaneous, intramuscular, intranasal, sublingual, buccal, intradural, intraocular, 5 intrarespiratory, or nasal inhalation and like forms of administration. Topical administration is generally preferred for the compositions and methods of the invention. Suitable dosage forms include dispersions, suspensions, solutions, aerosols, sponges, cotton applicators, and the like, with topical dosage forms such as shampoos being preferred.

The pharmaceutical compositions used in the methods of the present 10 invention include the active ingredients described above, and may also contain pharmaceutically acceptable carriers, excipients and the like, and optionally, other therapeutic ingredients.

The term "pharmaceutically acceptable salt" refers to a salt prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic or organic acids. 15 Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, sulfuric, and phosphoric. Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, 20 ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, algenic, and galacturonic. Examples of such inorganic bases, for potential salt formation with the sulfate or phosphate compounds of the invention, include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. Appropriate organic bases may be selected, for example, from N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, 25 ethylenediamine, meglumine (N-methylglucamine), and procaine.

The compositions for use in the methods of the present invention may include components such as suspensions, solutions and elixirs; aerosols; or other suitable carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like, with the topical preparations being 30 preferred.

Because of its ease of administration, a cream, lotion, or ointment represents the most advantageous topical dosage unit form, in which case liquid pharmaceutical

carriers may be employed in the composition. These creams, lotions, or ointments, may be prepared as rinse-off or leave-on products, as well as two stage treatment products for use with other skin cleansing or managing compositions. In a preferred embodiment, the compositions are administered as a rinse-off product in a higher concentration form, such as
5 a gel, and then a leave-on product in a lower concentration to avoid irritation of the skin. Each of these forms is well understood by those of ordinary skill in the art, such that dosages may be easily prepared to incorporate the pharmaceutical composition of the invention.

Pharmaceutical compositions for use in the methods of the present invention
10 suitable for topical administration may be presented as discrete units including aerosol sprays, each containing a predetermined amount of the active ingredient, as a powder, stick, or granules, as creams (*e.g.*, a conditioner), pastes, gels, lotions (*e.g.*, a sunscreen), syrups, or ointments, on sponges or cotton applicators, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid
15 emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association the carrier(s) with the active ingredient, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the
20 product into the desired presentation.

Other suitable dosage forms include tablets, troches, capsules, patches, gel caps, magmas, lozenges, plasters, discs, suppositories, nasal or oral sprays, and the like. When an oral dosage unit form is used instead of the preferred topical dosage form, tablets, capsules, and gel caps are preferred, in which case solid pharmaceutical carriers may be
25 employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

In addition to the common dosage forms set out above, the compound for use in the methods of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, the disclosures of which are expressly
30 incorporated herein by reference thereto.

For example, a tablet may be prepared by compression or molding, optionally, with one or more accessory ingredients. Compressed tablets may be prepared by

compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.

5 Desirably, each unit dose, *e.g.*, gel, cream, or ointment, contains from about 1 mg to 2,000 mg of the active ingredient, preferably about 200 mg to 1,600 mg, and more preferably about 600 mg to 1,000 mg of the composition.

EXAMPLES

10 The invention is further defined by reference to the following examples describing in detail the preparation of the compound and the compositions used in the methods of the present invention, as well as their utility. The examples are representative, and they should not be construed to limit the scope of the invention.

15 Example 1: Skin Cleanser Formulation

A pharmaceutical composition according to the invention may be prepared for cleansing skin as set forth below:

	Ingredient	Trade Name/Supplier	% by Weight
20	Part A		
	Deionized Water	N/A	49.2
	Trisodium Ethylene-Diamine-Tetraacetic Acid (EDTA)	HAMP-ENE Na ₃ T/Akzo Nobel	0.2
	Sodium Laureth-13 Carboxylate	SURFINE WLL/Finetex	10
25	Disodium Laureth Sulfosuccinate	MACKANATE EL/McIntyre Group	17
	Disodium Cocoamphodiacetate	MONATERJC CDX-38/Mona	11
	PEG-150 Pentaerythrityl Tetrastearate	CROTHIX/Croda	1.5
	PEG-150 Distearate	KESSCO PEG 6000 DS/Stepan	.7
30	Methylparaben	N/A	0.2
	Part B		
	Salicylic Acid	Salicylic Acid, powder, USP/Spectrum	1.6
	Citric Acid	N/A	1.5

	Triclosan	IRGASAN DP300/Ciba	0.3
Part C	PPG-26-Buteth-26, PEG-40 Hydrogenated Castor Oil	SOLUBILISANT LR1/Les Colorant Wackherr SA	2
5	Fragrance (Parfum)	Fragrance - BELL #J7393/Bell Flavors and Fragrances	0.3
	Menthol	Menthol Crystals, USP	0.1
Part D	Butylene Glycol, Deionized water, Black Cohosh (<i>Cimicifuga Racemosa</i>) Extract	ACTIPHYTE OF BLACK SNAKEROOT BG50/Active Organics	0.1
10	Butylene Glycol, Deionized water, Camellia Oleifera Extract	ACTIPHYTE OF JAPANESE GREEN TEA BG50/Active Organics	0.1
	Sodium Peroxylinecarbolic Acid (PCA)	AJDEW-50/Ajinomoto	0.2
	Cocamidopropyl PG- Dimonium Chloride Phosphate	PHOSPHOLIPID PTC/Mona	1
Part E	Hydrogen Peroxide	Hydrogen Peroxide, 35% solution, technical	3
15			100%
20	HAMP-ENE Na ₃ T is commercially available from Akzo Nobel Inc. of Dobbs Ferry, NY; SURFINE WLL is commercially available from Finetex, Inc. of Elmwood Park, NJ; MACKANATE EL is commercially available from McIntyre Group of University Park, IL; MONATERIC CDX-38 and PHOSPHOLIPID PTC are commercially available from Mona Industries Inc. of Patterson, NJ; CROTHIX is commercially available from Croda Inc. of Parsippany, NJ; KESSCO PEG 600 DS is commercially available from Stepan Co. of Northfield, IL; IRGASAN DP300 is commercially available from Ciba Specialty Chemicals Corp. of Albemarle, NC; SOLUBILISANT LR1 is commercially available from Les Colorant Wackherr SA of St. Ouen L'Aumone, France; BELL #J7393 is commercially available from Bell Flavors and Fragrances of Northbrook, IL; ACTIPHYTE OF BLACK SNAKEROOT BG50 and ACTIPHYTE OF JAPANESE GREEN TEA BG50 are commercially available from Active Organics of Dallas, TX; and AJDEW -50 is commercially available from Ajinomoto USA Inc. of Teaneck, NJ.		

Deionized water was metered into the processing tank and mixing

25 subsequently begun. The water was heated to 75°C and the remainder of Part A was added and mixed until uniform. The mixture was cooled to 60°C and the Part B ingredients were added and mixed until uniform. The mixture was then cooled to 50°C. In a separate vessel, Part C was premixed until uniform and then added to the mixture of Parts A and B. Parts A, B, and C were mixed until uniform and cooled to 40°C. The Part D ingredients were added

30 and mixed until uniform, then cooled to 30°C. Part E was added and mixed until uniform, resulting in a colorless, clear, slightly viscous fluid having a pH at 25°C of between 4 to 4.5 and a viscosity between 3,000 to 4,000 cps (RVT: #4 @ 10 rpm @ 25°C).

Example 2: Advanced Acne Prone Skin Formulation

A pharmaceutical composition according to the invention may be prepared for treating skin prone to acne as set forth below:

5				
		Ingredient	Trade Name/Supplier	% by Weight
	Part A	Deionized Water	N/A	46.7
		Hydroxyethylcellulose	CELLOSIZE	1
			QP52,000H/Amerchol	
10	Part B	Tetrasodium Ethylene-Diamine-Tetraacetic Acid (EDTA)	HAMP-ENE 220/Akzo Nobel	0.1
		Butylene Glycol	1,3-butylene glycol/Ashland	5
		Aloe Barbadensis Gel	Aloe Vera Freeze Dried	0.1
			Powder 200:1/Aloe	
15		Methyl Gluceth-10	GLUCAM E-10/Amerchol	3
		Witch Hazel (<i>Hamamelis Virginiana</i>) Distillate	Witch Hazel Distillate, 14%	3
		Zinc Acetate	Zinc Acetate, crystals, USP/FCC	0.5
20		Orange (<i>Citrus Aurantium Dulcis</i>) Extract	NATURAL ORANGE EXTRACT #71689/	0.3
			Flavurence	
		Dipotassium Glycyrrhizate	N/A	0.3
25		Lecithin, Tocopherol and Magnesium Ascorbyl Phosphate	OXYSOMES/Barhett	0.3
		Palmitoyl	GLYCOSPHERE PCO/Kobo	0.2
		Hydroxypropyltrimonium Amylopectin/Glycerin		
30		Crosspolymer, Lecithin, Grape (<i>Vitis Vinifera</i>) Seed Extract		

5		Palmitoyl	GLYCOSPHERE GT/Kobo	0.5
		Hydroxypropyltrimonium		
		Amylopectin/Glycerin		
		Crosspolymer, Lecithin,		
		<i>Camellia Sinensis</i> Extract		
10		<i>Epilobium Angustifolium</i>	Canadian Willowherb Whole	0.5
		Extract	Extract (5% in water)/Fytokem	
		Butylene Glycol and Water	ACTIPHYTE OF ARNICA	0.5
		and <i>Arnica Montana</i> Extract	BG50/Active Organics	
	Part C	Alcohol (denatured)	SD Alcohol 40-B, Anhydrous/	20
15		Salicylic Acid	Salicylic Acid, powder,	1
			USP/FCC/Spectrum	
	Part D	Triclosan	IRGASAN DP300/Ciba	0.4
		PPG-5-Ceteth-20	PROCETYL AWS/Croda	1
		PEG-40 Hydrogenated Castor Oil	CREMOPHOR RH-40/BASF	0.6
20		Retinol and Polysorbate 20	RETINOL 50C/BASF	0.1
		Phytonadione	N/A	0.1
		Linoleic Acid	EMERSOL 315/Henkel	0.3
	Part E	Glycolic Acid	GLYPURE=70% Glycolic Acid/DuPont	9
	Part F	Deionized water	N/A	2
25		Sodium Hydroxide	Sodium Hydroxide, pellets,	2
			USP/NF	
30	Part G	Hydrogen Peroxide	Hydrogen Peroxide, 35% solution, technical	<u>1.5</u>

100%

CELLOSIZES QP52,000H and GLUCAM E-10 are commercially available from Amerchol Corp. of Edison, NJ; HAMP-ENE 220 is commercially available from Akzo Nobel Inc. of Dobbs Ferry, NY; Aloe Vera Freeze Dried Powder 200:1 is commercially available from Aloe Corp. of TX; OXYSOMES is commercially available from Barnet Products Corporation of Englewood Cliffs, NJ; Canadian Willowherb Whole Extract (5% in water) is commercially available from Fytokem, Inc. of Saskatoon, SK CANADA; GLYCOSPHERE PCO and GLYCOSPHERE GT are commercially available from Kobo Products Inc. of South Plainfield, NJ; ACTIPHYTE OF ARNICA BG50 is commercially available from Active Organics of Dallas, TX; PROCETYL AWS is commercially available from Croda Inc. of Parsippany, NJ; CREMOPHOR RH-40 and

RETINOL 50C are commercially available from BASF Corporation of Budd Lake, NJ;
 GLYPURE=70% Glycolic Acid is commercially available from DuPont of Wilmington, DE;
 EMERSOL 315 is commercially available from Henkel Corp. of Hoboken, NJ.

Deionized water was metered into the processing tank and mixing
 5 subsequently begun. CELLOSIZE QP52,000H was sprinkled in, heated to 70°C, and
 mixed until clear and uniform. The mixture was cooled to 40°C. Part B ingredients were
 added in the order above, with sufficient mixing after each ingredient was added. The
 mixture was cooled to 25°C and premixed Part C ingredients were added and mixed until
 uniform. In a separate tank, Part D was heated to 40°C until the solids were dissolved and
 10 then added to the batch of Parts A, B, and C. The mixture was mixed until uniform, then
 Part E was added and mixed until uniform. Premixed Part F was slowly added in
 increments as needed to obtain the desired pH of 3.3 to 3.8 at 25°C, then Part G was added
 and mixed until completely uniform. This resulted in a straw-colored, clear to slightly hazy,
 slightly viscous liquid having a pH @ 25°C of 3.3 to 3.8 and a viscosity between 400 to
 15 800 cps (RVT: #2 @ 10 rpm @ 25°C).

Example 3: Skin Perfecting Lotion

A pharmaceutical composition according to the invention may be prepared
 20 for treating skin as set forth below:

	Ingredient	Trade Name/Supplier	% by weight
	Part A Water (Aqua)	Deionized water	63.6
	Carbomer	CARBOPOL ULTREZ 10/ B.F. Goodrich	0.3
25	Sclerotium Gum	AMIGEL/Tri-K	0.6
	Glycerin	Glycerin 99.5%/Ashland	6.0
	Butylene Glycol	1,3-butylene glycol/Ashland	6.0
	Allantoin	Allantoin/ISP	0.6
30	Panthenol	DEXPANTHENOL/Roche	0.6
	Tetrasodium EDTA	HAMP-ENE 220/Akzo	0.2
	Methylparaben	Methylparaben/Ueno	0.3

		Sodium PCA	AJIDEW-50/Ajinomoto	0.5
	Part B	Dicapryl Maleate	BERNEL ESTER DCM/Bemel	6.0
		Squalene	PHYTOLANE/Barnet	0.8
5		Sorbitan Stearate	ARLACEL 60/ICI	1.5
		Stearic Acid	EMERSOL 132/Henkel	1.3
		Dimethicone	DOW CORNING 200, 350 cs./Dow Corning	0.8
		C12-C15 Alkyl Benzoate	FINSOLV TN/Finetex	3.0
10		Cetearyl Alcohol and Ceteareth	HEXOTOL D/Heterene	0.6
		Propylparaben	Propylparaben/Ueno	0.2
	Part C	Water (Aqua)	Deionized water	0.3
		Triethanolamine	Triethanolamine 99%/Ashland	0.3
	Part D	Orange (<i>Citrus Aurantium</i> <i>Dulcis</i>) Extract	NATURAL ORANGE EXTRACT #71689/Flavurence	0.3
15		Diazolidinyl Urea	GERMALL II/ISP	0.3
		Glycolipids and Hyaluronic Acid	PHYTO/CER HA/Tri-K	0.3
		Palmitoyl	GLYCOSPHERES PCO/Kobo	0.3
		Hydroxypropyltrimonium		
20		Amylopectin/Glycerin		
		Crosspolymer and Lecithin and grape (<i>Vitis Vinifera</i>) Seed Extract		
		Palmitoyl	GLYCOSPHERES GT/Kobo	0.3
		Hydroxypropyltrimonium		
25		Amylopectin/Glycerin		
		Crosspolymer and Lecithin and <i>Camellia Sinensis</i> Extract		
		Propylene Glycol	Propylene Glycol/Ashland	0.6
		Algae Extract	HAWAIIAN SEAPLANT EXTRACT-J/Tri-K	0.2
30		Lecithin and Tocopherol and Magnesium Ascorbyl Phosphate	OXYSOMES/Barnet	0.6

	Butylene Glycol and Honey	ACTIPLEX 1072/Active	1.1
	Extract (Mel) and Meadowsweet	Organics	
	(<i>Spiraea Ulmaria</i>) Extract		
5	Talc and C9-C13 Fluoroalcohol	PF-5 TALC JA-46R/Kobo	0.8
	and Phosphoric Acid		
	Hydrolyzed Soy Flour	RAFFERMINE/R.I.T.A.	0.3
	Oat (<i>Avena Sativa</i>) Protein	REDUCTINE/R.I.T.A.	0.3
	Phytonadione	Phytonadione/Roche	0.01
10	Retinol and Polysorbate 20	RETINOL 50C/BASF	0.1
	<i>Epilobium Angustifolium</i> Extract	Canadian Willowherb Whole	0.5
		Extract (5% in water)/Fytokem	
	<i>Arnica Montana</i> Extract	ACTIPHYTE OF ARNICA	0.5
		BG50/Active Organics	
			100.0
15	CARPOL ULTREZ 10 is commercially available from B.F. Goodrich Co. of Richfield, OH; AMIGEL, PHYTO/CER and HAWAIIAN SEA PLANT EXTRACT are available from Tri-K-Chemical of Fairview, MT; Allantoin and GERMALL II are available from ISP Chemicals Inc. of Calvert City, KY; DEXPANTHENOL and Phytonadione are available from Roche Holdings, Inc. of Wilmington, DE; Methylparaben and Propylparaben are commercially available from Ueno Fine Chemicals Inc. of New York, NY AJIDEW N-50 is commercially available from Ajinomoto USA Inc. of Teaneck, NJ; BERNEL ESTER is commercially available from Bernel Chemical Co. of Englewood, NJ; PHYTOLANE is commercially available from Barnet Products Corporation of Englewood Cliffs, NJ; ARLACEL 60 is commercially available from ICI Americas Inc. of Wilmington, DE; EMERSOL 132 is commercially available from Henkel Corp. of Hoboken, NJ; DOW CORNING 200, 350 cs. is commercially available from Dow Corning Corp. of Auburn, MI; FINSOLV TN is commercially available from Finetex Inc. of Elmwood Park, NJ; HETOXOL D is commercially available from Heterene Chemical Co. of Paterson, NJ; NATURAL ORANGE EXTRACT #71689 is commercially available from Flavurence Corp. of Annandale, NJ; ACTIPLEX 1072 is commercially available from Active Organics Inc. of Lewisville, TX; PF-5 TALC JA-46R is commercially available from Kobo Products Inc. of South Plainfield, NJ;		
25	RAFFERMINE and REDUCTINE are commercially available from RITA Chemical Corp of East Northport, NY.		

The Skin Perfecting Lotion was prepared by metering deionized water into a processing tank and mixing at high speed. CARBOPOL ULTREZ 10 was sprinkled in. When the CARBOPOL ULTREZ 10 was completely dispersed, AMIGEL was added and

30 the mixture mixed until smooth and uniform. The mixture was heated to 80°C, the remaining Part A ingredients were added, and then mixed until uniform. In a separate tank, the Part B ingredients were combined and heated to 80°C until all the solids were

completely dissolved. Part B was added to Part A and the resulting batch was mixed until uniform. Premixed Part C was added and the batch mixed until homogeneous. The batch was cooled to 40°C and the Part D ingredients were added and mixing continued until the temperature of the mixture was 35°C. The resulting Skin Perfecting Lotion was a light
 5 beige, opaque, viscous lotion having a pH at 25°C of 6.2 to 7.2 and a viscosity of 14,000 to 24,000 cps. (RVT: #5 @10 rpm @ 25°C).

Example 4: Acne Management Formula

A pharmaceutical composition according to the invention may be prepared
 10 for managing acne as set forth below:

	Ingredients	Trade Name/Supplier	% by weight
15	Part A Water (Aqua)	Deionized Water	56.8
	Sclerotium Gum	AMIGEL/Alban Muller	0.4
	Disodium EDTA	HAM-ENE NA ₂ /Akzo	0.3
	Allantoin	Allantoin/ISP	0.2
	Methylparaben	Methylparaben/Ueno	0.3
	Zinc Oxide	66 ZINC OXIDE	0.3
20		U.S.P./Whitaker, Clark & Daniels	
25	Part B Water (Aqua)	Deionized Water	10
	Hydrolyzed Oat Flour and Oat Betaglucan	RITAVENA 5/R.I.T.A.	2.8
	Dicaprylyl maleate	BERNEL ESTER DCM/Bernel	3
	Glyceryl Stearate and PEG-100 Stearate	ARLACEL 165/ICI	3
	Cetearyl Alcohol and Cetareth-20	HEXOTOL D/Heterene	3
30	Propylparaben	Propylparaben/Ueno	0.1
Part D	Salicylic Acid	Salicylic Acid, powder, U.S.P.-N.F./Spectrum	1.3

	Sulfur	Sulfur, precipitated, U.S.P.- N.F./Spectrum	6.5
Part E	Water (Aqua)	Deionized Water	3
5	Sodium Hydroxide	Sodium Hydroxide, pellets, U.S.P.-N.F./Spectrum	0.1
	Glycolic Acid	GLYPURE 70% GLYCOLIC ACID/DuPont	6.5
Part F	Orange (<i>Citrus Aurantium Dulcis</i>) Extract	ORANGE EXTRACT PRODUCT #61522/Sunkist	1.1
10	Diazolidinyl Urea	GERMALL II/ISP	0.4
	Dipotassium Glycyrrhizate	Dipotassium Glycyrrhizinate/Int'l Sourcing	0.3
	Lecithin and Tocopherol and Magnesium Ascorbyl Phosphate	OXYZOMES/Barnett	0.3
15	Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer and Lecithin and	GLYCOSPHERES PCO/Kobo	0.3
20	Grape (<i>Vitis Vinifera</i>) Seed Extract		
			100.0

25 AMIGEL is commercially available from Alban Muller International of Vincennes, France; HAM-
ENE NA₂ is commercially available from Akzo Chemicals Inc. of Deer Park, TX; 66 ZINC OXIDE
U.S.P. is commercially available from Whitaker, Clark & Daniels of South Plainfield, NJ; Salicylic
Acid, powder, U.S.P.-N.F., Sulfur, precipitated, U.S.P.-N.F. and Sodium Hydroxide, pellets,
U.S.P.-N.F. are commercially available from Spectrum Mfg. Corp of New Brunswick, NJ;
ORANGE EXTRACT PRODUCT #61522 is commercially available from Sunkist Growers, Inc. of
Van Nuys, CA; Dipotassium Glycyrrhizinate is commercially available from International Sourcing
Inc. of Upper Saddle River, NJ.

30 The Acne Management Formula was prepared by metering deionized water
into a processing tank and mixing at high speed. AMIGEL was sprinkled in. When the
AMIGEL was completely dispersed, the mixture was heated to 85°C and the remaining Part
A ingredients were added and the mixture mixed well after each addition. In a separate

tank, Part B was heated to 100°C, mixed until smooth, cooled to 80°C and added to the batch. The resulting batch was mixed well. In another tank, the Part C ingredients were heated to 75°C. When all the solids dissolved, Part C was added to the batch, the batch was mixed until smooth and uniform, and the batch cooled to 50°C. Part D ingredients were
 5 added to the batch, the batch was homogenized for 5 to 10 minutes until the batch was smooth and uniform, and the batch was cooled to 40°C. The deionized water of part E was premixed with the sodium hydroxide pellets and the resulting solution was mixed well until all solids were dissolved. While mixing the solution, glycolic acid was slowly added in increments and the solution was mixed until homogeneous. The solution was added to the
 10 batch and the Part F ingredients were added to the batch. The batch was mixed and cooled to 35°C. The Acne Management Formula was a light yellow, opaque smooth lotion having a pH at 25°C of 3.8 to 4.8 and a viscosity of 10,000 to 20,000 cps. (RVT: #5 @10 rpm @ 25°C).

15 Example 5: Clarifying Skin Cleanser

A pharmaceutical composition according to the invention may be prepared for managing acne as set forth below:

	Ingredients	Trade Name/Supplier	% by weight
20	Part A Water (Aqua)	Deionized Water	48.5
	Sodium Lauroyl Oat Amino Acid	PROTEOL O.A.T./Seppic	2
	Decyl Glucoside	ORAMIX NS-10/Seppic	3
	Cocamidopropyl Betaine	AMPHOSOL CA/Stephan	12.5
25	Disodium Laureth Sulfosuccinate	MACKANATE EL/McIntyre	24
	PEG-120 Methyl Glucose Dioleate	GLUCAMATE DOE-120/Amerchol	3.5
	Methylparaben	Methylparaben/Ueno	0.2
30	PEG-150 Pentaerythrityl Tetrastearate	CROTHIX/Croda	0.25

5	Part B	Salicylic Acid	Salicylic Acid, powder, USP/Spectrum	2
		Tetrasodium EDTA	HAMP-ENE-100/Akzo	0.3
		Triclosan	IRGASAN D300/Ciba Specialty Chemicals	0.2
10	Part C	PPG-26-Buteth-26 and PEG 40Hydrogenated castor Oil	SOLUBILISANT LRI/ Whittaker, Clark & Daniels	2
		Fragrance	Fragrance-BELL #J7393/ Bell	0.3
		Menthol	Menthol Crystals, USP/ Spectrum	0.1
15	Part D	Butylene Glycol and water (aqua) and Black Cohosh (Cimicifuga Racemosa) Extract	ACTIPHYTE OF BLACK SNAKEROOT BG50/Active Organics	0.2
		Butylene Glycol and water (aqua) and Camellia Oleifera Extract	ACTIPHYTE OF JAPANESE GREEN TEA BG50/Active Organics	0.2
		Sodium PCA	AJIDEW N-50/Ajinomoto	0.4
		Imidazolidinyl Urea	GERMALL 115/ISP	0.35
				100.0
20	PROTEAL O.A.T. is commercially available from Seppic Inc. of Fairfield, NJ ; AMPHOSOL CA is commercially available from Stephan Co. Inc. of Fort Lauderdale, FL ; GLUCAMATE DOE-120 is commercially available from Amerchol Corp. of Edison, NJ; HAMP-ENE-100 is commercially available from Akzo Nobel Inc. of Dobbs Ferry, NY; SOLUBILISANT LRI is commercially available from Whitaker, Clark & Daniels of South Plainfield, NJ; GERMALL 115 is commercially available from ISP Chemicals Inc. of Calvert City, KY.			

25 The Clarifying Skin Cleanser was prepared by metering deionized water into a processing tank, mixing, and heating to 75°C. The part A ingredients were added and mixed until all the solids dissolved. The resulting mixture was cooled to 60°C. In a separate vessel the Part B ingredients were combined. The Part B ingredients were then added to Part A and the resulting batch was mixed until uniform. The resulting mixture was

30 cooled to 50°C. In a separate vessel the Part C ingredients were mixed until uniform. The part C ingredients were added to the batch and the resulting batch was mixed until uniform. The batch was cooled to 40°C and the part D ingredients were added and mixing continued

until uniform followed by cooling to 30°C. The Clarifying Skin Cleanser Formula was a pale yellow, slightly viscous liquid having a pH at 25°C of 4.5 to 5.5 and a viscosity of 5,000 to 9,000 cps. (RVT: # @10 rpm @ 25°C).

5

Example 6: Antimicrobial Effectiveness of the Invention - Advanced Acne Prone Skin Formulation

10

Culture Preparation

Escherichia coli (ATCC # 8739), *Staphylococcus aureus* (ATCC # 6533), *Pseudomonas aeruginosa* (ATCC # 9027) were each propagated in Trypticase Soy Broth (TSB) at 35°C for 24 hrs. *Candida albicans* (ATCC # 10231), and *Aspergillus niger* (ATCC # 16404) were propagated in Yeast and Mold Broth (YM) at 24°C for 72 h. One loop of each bacteria culture was streaked onto Trypticase Soy Agar (TSA) and the yeast and mold onto Sabouraud Dextrose Agar (SDA). The bacterial and yeast cultures were incubated for 24 h at 35°C and 48 h at 24°C, respectively. The mold culture was incubated for 5 days at 24°C. Following appropriate incubation, the surface growth of the organisms were washed with sterile Saline TS. Additional saline was added to reduce the microbial count. Each respective cell suspension was further diluted with sterile saline TS to an appropriate concentration.

25

Product Inoculation

Five 20-g portions of the Advanced Acne Prone Skin Formula of Example 2 was aseptically placed into sterile bottles. Each bottle was independently inoculated with 0.1 mL of the inoculum suspension.

30

Target Inoculation Concentration

A final concentration of 10^5 and 10^6 cfu/g of product was obtained. This spike suspension was assayed for each respective organism to determine the initial microbial load in the product. All enumeration analyses were performed by preparing serial

10-fold dilutions in Butterfield's Phosphate Buffered Diluent (BPBD), and then plated using the pour plate technique on respective media.

Test Intervals

- 5 An enumeration of the target organisms were performed on each inoculum. Immediately after inoculation (less than 1 minute), each product was assayed to determine the density of viable target organisms according to the pour plate technique. Each sample was tested again after 2 and 4 minutes. A 1-g portion was removed and mixed with 9.9 mL of BPBD. Serial dilutions were prepared as appropriate. Test samples containing bacterial
- 10 cultures were plated with TSA and incubated for 48 h at 35°C. Samples containing yeast and mold were plated with SDA and incubated for 5 days at 24°C.

Results

The following results were obtained for each of the five organisms.

- 15 Test Organism: *Candida albicans* (ATOC # 10231)
Theoretical Inoculum Level: 400,000 cfu/g

20	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Advanced Acne Prone Skin Formula
	0 (less than 1)	<10
	2	<10
	4	<10

- Test Organism: *Aspergillus niger* (ATCC # 16404)
25 Theoretical Inoculum Level: 160,000 cfu/g

30	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Advanced Acne Prone Skin Formula
	0 (less than 1)	<10
	2	<10
	4	<10

Test Organism: *Escherichia coli* (ATCC # 8739)

Theoretical Inoculum Level: 1,000,000 cfu/g

5	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Advanced Acne Prone Skin Formula
	0 (less than 1)	<10
	2	<10
	4	<10

10

Test Organism: *Staphylococcus aureus* (ATCC # 6538)

Theoretical Inoculum Level: 700,000

15	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Advanced Acne Prone Skin Formula
	0 (less than 1)	<10
	2	<10
	4	<10

Test Organism: *Pseudomonas aeruginosa* (ATCC # 9027)

20 Theoretical Inoculum Level: 260,000

25	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Advanced Acne Prone Skin Formula
	0 (less than 1)	<10
	2	<10
	4	<10

Discussion and Conclusion

The Advanced Acne Prone Skin Formulation prepared according to the present invention exhibited excellent antimicrobial properties. In less than one minute there
 30 was greater than a 99.99% reduction in levels of *Candida albicans*, *Escherichia coli*,
Staphylococcus aureus, *Pseudomonas aeruginosa*, and *Aspergillus niger*.

Example 7: Antimicrobial Effectiveness of Another Formulation of the Invention - Clarifying Skin Cleanser

Culture Preparation

5 *Escherichia coli* (ATCC # 8739), *Staphylococcus aureus* (ATCC # 6533),
and *Pseudomonas aeruginosa* (ATCC # 9027) were propagated in Trypticase Soy Broth
(TSB) at 35°C for 24 h. *Candida albicans* (ATCC # 10231) and *Aspergillus niger* (ATOC
16404) were propagated in Yeast and Mold Broth (YM) at 24°C for 72 h. One loop of
each bacteria culture was streaked onto Trypticase Soy Agar (TSA) and the yeast and mold
10 onto Sabouraud Dextrose Agar (SDA). The bacterial and yeast cultures were incubated for
24 h at 35°C and 48 h at 24°C, respectively. The mold culture was incubated for 5 days at
24°C. Following appropriate incubation, the surface growth of the organisms were washed
with sterile Saline TS. Additional saline was added to reduce the microbial count. Each
respective cell suspension was further diluted with sterile saline TS to an appropriate
15 concentration.

Product Inoculation

Five 20-g portions of the Clarifying Skin Cleanser of Example 1 was
aseptically placed into sterile bottles. Each bottle was independently inoculated with 0.1
20 mL of the inoculum suspension.

Target Inoculation Concentration

A final concentration of 10^5 and 10^6 cfu/g of product was obtained. This
spike suspension was assayed for each respective organism to determine the initial
25 microbial load in the product. All enumeration analyses were performed by preparing serial
10-fold dilution's in Butterfield's Phosphate Buffered Diluent (BPBD), and then plated
using the pour plate technique on respective media.

30

Test Intervals

An enumeration of the target organisms were performed on each inoculum. Immediately after inoculation (less than 1 minute), each product was assayed to determine the density of viable target organisms according to the pour plate technique. Each sample
 5 was tested again after 2 and 4 minutes. A 1-g portion was removed and mixed with 9.9 mL of BPBD. Serial dilutions were prepared as appropriate. Test samples containing bacterial cultures were plated with TSA and incubated for 48 h at 35°C. Samples containing yeast and mold were plated with SDA and incubated for 5 days at 24°C.

10

Results

The following results were obtained for each of the five organisms.

Test Organism: *Candida albicans* (ATOC # 10231)

Theoretical Inoculum Level: 400,000 cfu/g

15	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Clarifying Skin Cleanser
	0 (less than 1)	25,000
	2	20,000
20	4	14,000

Test Organism: *Aspergillus niger* (ATCC # 16404)

Theoretical Inoculum Level: 160,000 cfu/g

25	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Clarifying Skin Cleanser
	0 (less than 1)	1,400
	2	1,200
	4	1,000

30

Test Organism: *Escherichia coli* (ATCC # 8739)

Theoretical Inoculum Level: 1,000,000 cfu/g

5	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Clarifying Skin Cleanser
	0 (less than 1)	<10
	2	<10
	4	<10

Test Organism: *Staphylococcus aureus* (ATCC # 6538)

10 Theoretical Inoculum Level: 700,000

15	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Clarifying Skin Cleanser
	0 (less than 1)	<10
	2	<10
	4	<10

Test Organism: *Pseudomonas aeruginosa* (ATCC # 9027)

Theoretical Inoculum Level: 260,000

20	Testing Schedule (Time: minutes)	Recovery Levels (cfu/g)
		Clarifying Skin Cleanser
	0 (less than 1)	<10
	2	<10
	4	<10

25

Discussion and Conclusion

The Clarifying Skin Cleanser exhibited excellent antimicrobial properties.

In less than one minute there was a >99.99% reduction in levels of *Escherichia coli*,

Staphylococcus aureus, and *Pseudomonas aeruginosa*. In less than one minute, levels of

30 *Aspergillus niger* and *Candida albicans* were reduced by 99.1% and 94.0%, respectively.

Example 8: Irritation Test Using the Invention

Irritation potential following epidermal contact by compositions prepared according to the invention was examined. Fifty-three subjects ranging from 18 to 77 were evaluated. The patients were administered 0.2 mL, or an amount sufficient to cover the
5 upper back between the scapulae, of a 10 percent dilution of the formulation used in Example 2. The administration occurred by applying the composition to a 1" x 3/4" absorbent pad portion of an adhesive dressing, which was secured to the treatment site on each patient. The test material remained in contact for a total of 48 hours, and the test sites were evaluated at that time and at 72 hours (24 hours later) for changes using a 6-point scale
10 ranging from no visible skin reaction up to severe erythema, possible edema, vesiculation, bullae and/or ulceration. One test subject did not complete the study. Observations indicated negative irritation throughout the test interval, *i.e.* no visible skin reaction on a single patient.

15 Example 9: Hydrogen Peroxide Stability Test

The formulations prepared according to Examples 1 of the invention having hydrogen peroxide, citric acid, salicylic acid, an antibacterial agent, and an amphoteric surfactant were heated to between 40°C to 45°C for three months in an oven test. The oxygen content of the formula which was assayed after the stability test, showed no more
20 than 3 weight percent loss of the original hydrogen peroxide content. Such high stability provides an improved composition having a long shelf-life without substantial loss of efficacy.

Examples 10 - 12: Acne Treatment Regimen

25 An acne treatment regimen comprising Clarifying Cleanser, Advanced Acne Prone Skin Formula, Skin Perfecting Lotion and Acne Management Formula (Examples 1, 2, 3, and 4, respectively) was administered to 15 subjects. Subjects were evaluated after 2 weeks and 4 weeks use of the treatment regimen. Subjects were evaluated for total facial lesions, skin hydration and overall appearance of acne.

30

Testing of the Treatment Regimen

The acne treatment regimen comprising a ADVANCED ACNE PRONE SKIN FORMULA, SKIN PERFECTING LOTION, ACNE MANAGEMENT FORMULA, and CLARIFYING SKIN CLEANSER, prepared according to Examples 2, 3, 4, and 5, respectively, was administered to 15 subjects who exhibited a Grade 2-4 acne condition according to the grading scale provided below:

- 0: Facial skin need not be perfectly clear. A few scattered comedones or papules may be present, but these should be visible only on close examination.
- 10 2: About one fourth of facial area is involved, with small papules and large or small comedones. A few pustules or large prominent papules may be present.
- 4: About half of facial area is involved, with small papules and large or small comedones. A few pustules or large prominent papules are usually present. (If lesions are large, subject may have Grade 4 severity, although less than half of facial area is involved).
- 15 6: About three-fourths of facial area is involved, with papules and/or large open comedones. (Lesser facial area of involvement is permissible if inflammatory lesions are large) numerous pustules are usually present, some of which may be large.
- 20 8: Practically all of facial area is involved, with lesions. Large prominent pustules are usually visible. Lesions are usually highly inflammatory. Other types of acne (such as conglobata, including sinus and cystic types).

On the first day of the study all subjects were acclimated to ambient temperature and relative humidity for fifteen minutes. After the equilibration period, a trained technician examined each subject's face and recorded the number of inflammatory and non-inflammatory lesions in each of six sections of the face. The lesions of the six sections were totaled to obtain a global assessment score for each subject. Clinical photographs were taken in various poses for each subject and three Corneometer measurements were taken.

Subjects were provided with the treatment regimen and were given the following instructions for the treatment regimen:

CLARIFYING CLEANSER: Apply twice per day (once in the morning and once in the evening). Pour a small amount into hand or wash

cloth. Apply to dampened face and neck. Massage gently into full lather. Rinse thoroughly with warm water and pat dry. Follow with ACNE PRONE SKIN FORMULA.

5 ACNE PRONE SKIN FORMULA: Apply after cleansing twice per daily (once in the morning and once in the evening). Apply a small amount to face and neck or areas affected with acne. Follow with SKIN PERFECTING LOTION.

SKIN PERFECTING LOTION: Use twice per day after cleansing and treating skin. Apply a small amount to face and neck.

10 ACNE MANAGEMENT FORMULA: Use twice a day after using CLARIFYING CLEANSER, ACNE PRONE SKIN FORMULA, and SKIN PERFECTING LOTION. Apply a small amount to affected area to spot treat.

Subjects were required to maintain a daily diary indicating date, time of use and comments.

Subjects were permitted to use their customary make-up products during the study.

15 However, subjects were instructed not to introduce any new cosmetic or facial treatment products during the study. Following the two week test material use period subjects were evaluated for an interim count of total facial lesions, Corneometer readings and clinical photographs. After four weeks of test material use subjects returned with their diaries for a final lesion count, Corneometer readings and clinical photographs. Standard paired t-tests were used to determine statistically significant differences between baseline and two (2) and
20 four (4) week total facial lesion counts and Corneometer readings. Statistical significance exists for all p-values less than or equal to 0.05 at the 95% confidence level. Improvement scores for the appearance of acne in clinical photographs were analyzed using Z-tests.

A total of fourteen subjects finished the study. One subject was disqualified immediately for lack of compliance with the Inclusion Criteria of the protocol. A review of
25 the daily diaries indicated that four (4) subjects reported redness, burning, stinging and/or "irritation" during the study period. One (1) of the subjects reported the onset of redness and burning on day five (5) of the study immediately after product application and lasting for fifteen (15) to twenty (20) minutes. The subject was instructed to discontinue test material use on day ten (10) of the study. On day fourteen (14) the subject was examined
30 by a doctor and no evidence of skin irritation was observed. The subject was instructed to begin use of the treatment material at this time. The subject reported no evidence of irritation until day twenty four (24) of the study and completed study participation. No

evidence of irritation was observed at the final visit. The subjects reaction was diagnosed as dermatitis. The remaining subjects reported symptoms following one (1) to two (2) uses of the test material and completed study participation without further complaints.

5 Example 10: Total Lesion Count Following Treatment Regimen

The acne present on the skin of each subject was evaluated by visual examination using the grading scale described herein. The number of lesions on the face were counted at each visit. The number of open and closed comedones, as well as papules and pustules, were recorded. A global assessment score, the total of all lesions, was
 10 recorded for each visit. Reductions in the global assessment score are indicative of a reduced incidence and/or severity of acne lesions. The data for total lesion count is provided below.

15	Total Lesion Count			
		Baseline	2 Weeks	4 Weeks
	Mean	44.4	33.4	27.6
	Mean Percent Difference from Baseline		-26%	-40%
	σ		30%	22%

20 The regimen showed a statistically significant decrease of twenty-six percent (26%) in the number of lesions observed after using the treatment regimen for two (2) weeks and a statistically significant decrease of forty (40%) after using the treatment regimen for four (4) weeks compared to baseline ($p=0.02$ and $p=1.07 \text{ E-}05$, respectively).

25 Example 11: Photographic Evaluation Following Treatment Regimen

Photographs of subjects were taken at designated visits using the Canfield Clinical System of imaging equipment. This particular system permits comparison of photographs to be made with the confidence that the only factors which may have changed are those resulting from treatment. This is achieved by precisely and reproducibly
 30 positioning the head of the subject and carefully controlling the lighting, film type and processing. Photographs were visually assessed and evaluated by a trained technician before

and after use of the test material. The following scoring scale was used for visual assessment of the skin:

- 5 1 = no improvement
 2 = slight improvement
 3 = mild improvement
 4 = moderate improvement
 5 = extreme improvement

Improvement scores for the appearance of acne in clinical photographs were analyzed using Z-tests. For the two (2) and four (4) week scores, the number of subjects exhibiting
 10 improvements scoring a two (2), three (3), four (4) or five (5) was compared to the number of subjects exhibiting no improvement, scored as a one (1). The improvement assessment of the overall appearance of acne, rated from clinical photographs, is provided below.

Photographic Evaluation							
15	Week 2	Score:	1	2	3	4	5
		Number of Subjects Assigned each Score	5	5	2	2	0
		Percentage	35.7%	64.3%			
		Z-Score	-1.12				
20	Week 4	Number of Subjects Assigned each Score	4	4	5	1	0
		Percentage	28.6%	71.4%			
		Z-Score	-1.77				

25 The number of subjects exhibiting improvement from baseline in the overall appearance of acne at two (2) weeks was greater than subjects with no improvement. The Z-score obtained at two (2) weeks corresponds to improved skin appearance having a statistical significance at a 74% confidence level. In the four (4) week photograph the
 30 number of subjects exhibiting improvement from baseline in the overall appearance of acne was greater than subjects with no improvement. The Z-score obtained at four (4) weeks corresponds to improved skin appearance having statistical significance at a 92% confidence level.

Example 12: Moisturization via Corneometer Following Treatment Regimen

Changes in skin hydration were measured with a CORNEOMETER which is a commercially available instrument (CM-820, Courage and Khazaka Germany) designed to measure changes in the capacitance of the skin resulting from small changes in the degree of hydration. The CORNEOMETER expresses the capacitance of the skin in arbitrary unit of skin hydration (H). The instrument is capable of measuring the moisture of the stratum corneum to a depth of 0.1 mm and is used to measure the effects of cosmetic preparations on the moisture content of the skin. Tests using the CORNEOMETER were conducted by taking 3 measurements, one at the right and left cheek and one at the center of the skin, for each subject. The three measurements were then averaged for each subject. The data for skin hydration (H) is provided below.

Skin Hydration (H)			
	Baseline	2 Weeks	4 Weeks
Mean	70.8	51.6	49.5
Mean Percent Difference from Baseline		-26%	-29%
σ		14%	12%

The regimen showed a statistically significant decrease in Skin Hydration, H, of twenty-six percent (26%) after using the treatment regimen for two (2) weeks and a statistically significant decrease of twenty-nine (29%) after using the treatment regimen four (4) weeks compared to baseline ($p=2.27 \text{ E-}05$ and $p=5.38 \text{ E-}06$, respectively). A loss in skin hydration is typically observed following treatment with anti-acne products.

Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. The foregoing disclosure includes all the information deemed essential to enable those skilled in the art to practice the claimed invention.

THE CLAIMS

What is claimed is:

1. A skin cleansing pharmaceutical composition comprising:
5 an acidic component comprising a hydroxy acid or tannic acid, or a pharmaceutically acceptable salt thereof, in an amount sufficient to exfoliate at least a portion of the skin;
hydrogen peroxide in an amount sufficient to cleanse the skin without substantial irritation thereof; and
10 an antimicrobial agent in an amount sufficient to at least inhibit microorganisms on the skin.
2. The pharmaceutical composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.
15
3. The pharmaceutical composition of claim 1, wherein the acidic component comprises an alpha-hydroxy acid, beta-hydroxy acid, or tannic acid, and the antimicrobial agent comprises a bactericide.
- 20 4. The pharmaceutical composition of claim 3, wherein the acidic component comprises glycolic acid, lactic acid, citric acid, salicylic acid, or tannic acid.
5. The pharmaceutical composition of claim 3, wherein the bactericide comprises triclosan.
25
6. The pharmaceutical composition of claim 4, further comprising an amount of amphoteric surfactant and an amount of citric acid sufficient to inhibit hydrogen peroxide decomposition for at least three months.
- 30 7. The pharmaceutical composition of claim 6, wherein the amount of amphoteric surfactant and citric acid is sufficient to inhibit hydrogen peroxide decomposition at 40°C for at least three months.

8. The pharmaceutical composition of claim 1, wherein the acidic component is present in an amount from about 0.1 to 8 weight percent, the hydrogen peroxide is present in an amount from about 0.01 to 6 weight percent, and the antimicrobial agent is present in an amount from about 0.1 to 1.5 weight percent, of the composition.

5

9. The pharmaceutical composition of claim 1, further comprising at least one of a surfactant, a stabilizer, a preservative, a moisturizer, anti-inflammatory agent, anti-oxidant, and a coloring agent, which together may be present in an amount from about 10.1 to 99.1 weight percent of the composition.

10

10. A gel, paste, cream, lotion, emulsion, or ointment comprising the pharmaceutical composition of claim 1.

11. A method of managing a skin condition which comprises administering to a patient a therapeutically effective amount of: (1) an acidic component comprising a hydroxy acid or tannic acid, or a pharmaceutically acceptable salt thereof, (2) hydrogen peroxide, and (3) an antimicrobial agent to at least inhibit the growth of microorganisms on the skin.

15

12. The method of claim 11, wherein the skin condition treated is at least one of seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, or impetigo.

20

13. The method of claim 11, wherein the acidic component, hydrogen peroxide, and antimicrobial agent are administered topically.

25

14. The method of claim 13, wherein the topical administration is by at least one of a gel, paste, cream, lotion, emulsion, or ointment.

15. The method of claim 14, wherein about 1 mg to 10,000 mg of the acidic component, hydrogen peroxide, and antimicrobial agent are together administered.

30

16. The method of claim 11, wherein the acidic component, hydrogen peroxide, and antimicrobial agent are administered concurrently.

17. The method of claim 11, wherein the acidic component, hydrogen peroxide, and antimicrobial agent are administered concurrently with at least one additional pharmaceutical composition for the prevention or treatment of a skin condition.

5 18. The method of claim 11, which further comprises administering at least one of a surfactant, stabilizer, preservative, moisturizer, anti-inflammatory agent, anti-oxidant, or coloring agent.

19. The method of claim 11, wherein the acidic component comprises an alpha-
10 hydroxy acid, beta-hydroxy acid, or tannic acid and the antimicrobial agent comprises a bacteriocide.

20. The method of claim 19, wherein the acidic component comprises glycolic, lactic, tannic, citric, or salicylic acid, and the bacteriocide comprises triclosan.
15

20

25

30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17339

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 7/48, 33/40; A01N 31/02; C11D 3/48 US CL :514/25, 563; 424/65, 49; 423/273; 507/131 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/25, 563; 424/65, 49; 423/273; 507/131 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN/CAS ONLINE, MEDLINE, SCISEARCH, EMBASE, EUROPATFUL search terms: hydrogen peroxide, triclosan, hydroxy acids, antimicrobial agents																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X - Y	US 4,900,721 A (BANSEMIR et al) 13 February 1990, abstract and full text.	1-4, 8-9,11 and 13-19 ----- 5-7, 10, 12 and 20																		
X - Y	US 5,139,788 A (SCHMIDT) 18 August 1992, abstract and full text.	1-4, 8-9,11 and 13-19 ----- 5-7, 10, 12 and 20																		
Y	US 5,296,215 A (BURKE et al) 22 March 1994, column 5, lines 60-column 6, lines 10.	5 and 20																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*&*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 02 SEPTEMBER 1999		Date of mailing of the international search report 14 OCT 1999																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>D. Lawrence</i> VICKIE KIM Telephone No. 703-308-1235																		